Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme to buy GelTex in $1bn cash/stock deal

Executive Summary

Genzyme General is buying GelTex for about $1bn--$500mm in cash and $500mm in Genzyme common stock. Each GelTex share will be exchanged for $47.50 in cash or 0.7272 in stock (a premium of 27% based on the price of Genzyme stock at announcement), subject to proration to keep the cash part at 50%.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies